Newsfeeds - Spark Newswire

1 minute read

Analyst Ratings

Goldman Sachs Maintains Neutral Rating for HUTCHMED: Here’s What You Need To Know

Today, 4:42 PM

Goldman Sachs has decided to maintain its Neutral rating of HUTCHMED (China) (NASDAQ:HCM) and raise its price target from $14.00 to $16.00. Shares of HUTCHMED (China) are trading down 5.74% over the last 24 hours, at $13.13 per share.

HCM

1 minute read

HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting

By Vandana Singh

Today, 4:42 PM

HUTCHMED (China) Limited (NASDAQ:HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World…

AZN

6 minute read

83 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:42 PM

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.

ACLX

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 4:42 PM

AXDX

5 minute read

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

By The Bamboo Works

Today, 4:42 PM

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter

BGNE

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 4:42 PM

On Friday, 1043 companies hit new 52-week lows.

AAOI

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 4:42 PM

ACCD

3 minute read

31 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 4:42 PM

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition.

ACCD

1 minute read

U.S. FDA Rejects HUTCHMED’s New Drug Application For Surufatinib In Neuroendocrine Tumors

By Ragothaman Srinivasan

Today, 4:42 PM

HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs).

HCM

3 minute read

HUTCHMED Receives Complete Response Letter From The U.S. FDA For Surufatinib For The Treatment Of Advanced Neuroendocrine Tumors

By Benzinga Newsdesk

Today, 4:42 PM

HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration ("FDA" or the "Agency") has issued a Complete

HCM